Many Top Pharma & Biotechs Rise as Drug Price Disclosure Thrown Out
President Trump lost ground with his efforts to force drug companies to list drug prices on TV ads, with the effort being blocked on free speech concerns.
Coverage ended
2 updates · Last at 11:44am ET
Health Care Stocks (IBB) Live: President Trump Promises Lower Drug Prices, Stocks Moving
Live Updates
Newest firstPharmaceutical Stocks are Still Erasing Earlier Losses
Following the initial shock from President Trump’s drug cost announcement, many of the top pharmaceutical stocks are still rebounding higher.
Amgen (NASDAQ: AMGN), for example, is up more than 3.2%, or by $8.60 a share. AbbVie (NYSE: ABBV) is up just over 3.4%, or $6.35 a share. Bristol Myers Squibb (NYSE: BMY) is up just over 2.6%, or by $1.25 per share.
Even the iShares Biotechnology ETF (NASDAQ: IBB) is up 3.87%, or by $4.51 on the day.
Drug Stocks Are Expected to Be Okay
While drug companies and investors dreaded Trump’s announcement, it won’t take much away from leading pharmaceutical companies.
According to Barron’s, “It looks like it could be a blessing in disguise for drug makers, fundamentally restructuring the U.S. drug industry in a way that hurts pharmacy benefit managers.”
The new order focuses more on the direct-to-consumer market – an option that cuts out insurers and pharmacy benefit managers. We also have to consider that drug makers have spent a considerable amount of money attacking pharmacy benefit managers, whose rebates are blamed for higher U.S. drug prices, as also noted by Barron’s.
Live coverage has ended. The full story is below.
Full Coverage
The story so farPresident Trump will order drugmakers to lower the prices of medications. All to bring drug costs in line with what other countries pay.
According to Reuters, “White House officials said the government will give drug makers price targets in the next 30 days and will take further action to lower prices if those companies do not make significant progress towards those goals within six months of the order being signed.”
At the moment, Trump wants drug prices to come down “almost immediately” by 30% to 80%.
“The Pharmaceutical/Drug Companies would say, for years, that it was Research and Development Costs, and that all of these costs were, and would be, for no reason whatsoever, borne by the ‘suckers’ of America, ALONE,” said President Trump, as quoted by Truth Social.
While the news initially dragged some of the biggest drug stocks lower, many are now surging higher. Amgen (NASDAQ: AMGN | AMGN Price Prediction), for example, is up more than 3.2%, or by $8.60 a share. AbbVie (NYSE: ABBV) is up just over 2%, or $3.55 a share. Bristol Myers Squibb (NYSE: BMY) is up just over 2.6%, or by $1.25 per share.
Even the iShares Biotechnology ETF (NASDAQ: IBB) is up 3.7%, or by $4.35 on the day.
Contact [email protected] for any questions or corrections.
Ian Cooper
Ian Cooper is a veteran market analyst and investment strategist with more than 20 years of experience covering stocks, commodities, and macro trends. Since 1999, he has helped investors identify market opportunities using a blend of technical analysis, fundamental research, and market sentiment.
He is the creator of the ADD News Flow Strategy, which focuses on trading market reactions to major news events and investor psychology. Cooper was also among the analysts who warned about the 2008 financial crisis and major financial institution collapses ahead of the broader market.
Before joining 247 Wall St., Cooper wrote extensively for InvestorPlace and other financial publications, covering market trends, trading strategies, and investment opportunities.
